A study by the National Academies finds more support is needed for nearly 18 million people giving care to family members 65 and older.
U.S. trauma care experts are increasingly focusing on ways to help civilian victims of violence — whether the incidents were mass shootings or bad car accidents — avoid bleeding to death at the scene.
A federally funded research project in Baltimore has potential to help aging-in-place efforts elsewhere, a study in Health Affairs reports.
Dementia complicates pain management in hospice patients because communication is difficult and the cause of pain can be hard to identify, researchers report.
Residents with dementia need to be monitored and increased training is needed for staff who care for them, said researchers who examined reported instances of abuse in assisted living facilities.
Elderly black women suffer most from shorter active life expectancy free of disabilities, showing no improvement since the early 1980s, Health Affairs study finds.
Researchers say their study suggests solitary households may be markers for older adults in better health and with more functional independence.
As a Democratic senator and governor, Tim Kaine has backed the Affordable Care Act, Medicaid expansion and better access to mental health treatment for people in crisis.
A Kaiser Family Foundation analysis sheds new light on a widely-held belief about the costs of end-of-life care.
A study in JAMA finds palliative care counseling for families of chronically ill patients is not routinely needed by all and sometimes increases symptoms of post-traumatic stress.
A study in Health Affairs finds Medicare Part D beneficiaries were charged copays averaging 10.5 times more for Crestor and Nexium than generic drugs would have cost them.
A report from the National Academies of Sciences, Engineering and Medicine calls for the White House to lead a national strategy to promote and continue advances in trauma care.
The Food and Drug Administration has introduced a simplified form that doctors will use to seek FDA approval to treat seriously ill patients with experimental drugs after other options run out.